Prognostic risk model of LIHC T-cells based on scRNA-seq and RNA-seq and the regulation of the tumor immune microenvironment
This study introduces a T-cell marker-based prognostic risk model for LIHC patients. This model effectively predicted survival outcomes and immunotherapy effectiveness in LIHC patients, aligning with diverse immune responses and the distinct immunological profiles observed in the high-risk group.
Authors
- Jinghua Gao (ORCID: https://orcid.org/0000-0001-8714-3028)
- Lixian Wu (ORCID: https://orcid.org/0000-0002-6990-0918)
- Xiaomei Yi
- Chunxiao Huang (ORCID: https://orcid.org/0000-0001-6109-1135)
- Zihan Cai
- Shoupeng Ding
- Shouzhao Zheng
Institutions
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
- Dali University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1007/s12672-024-01424-z
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Natural Science Foundation of China